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Nasal NK/T-cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma (NHL) that is closely associated with Epstein–Barr
virus (EBV). The clonal expansion of EBV-infected NK or T cells is also seen in patients with chronic active EBV (CAEBV) infection,
suggesting that two diseases might share a partially similar mechanism by which EBV affects host cellular gene expression. To
understand the pathogenesis of EBV-associated NK/T-cell lymphoproliferative disorders (LPD) and design new therapies, we
employed a novel EBV DNA microarray to compare patterns of EBV expression in six cell lines established from EBV-associated
NK/T-cell LPD. We found that expression of BZLF1, which encodes the immediate-early gene product Zta, was expressed in SNK/T
cells and the expression levels were preferentially high in cell lines from CAEBV infection. We also analyzsd the gene expression
patterns of host cellular genes using a human oligonucleotide DNA microarray. We identified a subset of pathogenically and clinically
relevant host cellular genes, including TNFRSF10D, CDK2, HSPCA, IL12A as a common molecular biological properties of EBV-
associated NK/T-cell LPD and a subset of genes, such as PDCD4 as a putative contributor for disease progression. This study
describes a novel approach from the aspects of viral and host gene expression, which could identify novel therapeutic targets in EBV-
associated NK/T-cell LPD.
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Epstein–Barr virus (EBV) is a ubiquitous human herpesvirus that
establishes a lifelong persistent infection of B cells in more than
90% of the human adult population (Cohen, 2000; Kieff and
Rickinsonm, 2001) Primary infection by EBV is usually asympto-
matic, however, it sometimes results in infectious mononucleosis
(IM) which resolves spontaneously after the emergence of
EBV-specific immunity (Cohen, 2000). EBV is a B-lymphotropic
virus that is characterised by its ability to transform B cells in
vitro, and is associated with a variety of B-cell malignancies
including Burkitt lymphoma, non-Hodgkin lymphoma (i.e.,
pyothorax-associated lymphoma; PAL) and post-transplant
lymphoproliferative disorders (LPD) (Nakatsuka et al, 2002;
Thompson and Kurzrock, 2004). It is also demonstrated that
EBV is implicated in the pathogenesis of non-B-cell malignancies,
such as classical Hodgkin’s lymphoma, NK- or T-cell lymphomas,
nasopharyngeal carcinoma (NPC) and gastric carcinoma (Young
and Rickinson, 2004).
Like other types of herpesvirus, EBV can infect cells in either a
latent or a lytic manner. The EBV proteins associated with cellular
transformation, such as LMP-1, are expressed in certain forms of
latent infection, and most tumor cells in EBV-associated LPD
express transformation-associated viral proteins (Huen et al, 1995;
Zimber-Strobl et al, 1996; Kieff and Rickinsonm, 2001) Cellular
transformation results from the latent rather than the lytic form
of EBV infection, however, an increased level of lytically infected
cells in patients may nevertheless increase the likelihood of an
EBV-associated malignancy.
Although the molecular biology of EBV and B-cell transforma-
tion has been extensively studied for years, little is known about
the host–virus interaction in EBV-related NK- and T-cell
malignancies. Extranodal NK/T-cell, nasal type (hereafter, nasal
NK/T-cell lymphoma), is a distinct clinicopathologic entity highly
associated with EBV (Nava and Jaffe, 2005). Since necrosis is the
common feature of nasal NK/T-cell lymphoma, the biological
features of lymphoma cell are poorly understood because of the
difficulty in obtaining sufficient viable specimens. Some nasal
NK/T-cell lymphomas, develop from long-lasting EBV infection
termed chronic active EBV (CAEBV) infection. CAEBV infection
has high mortality and morbidity and its life threatening
characteristics include virus-associated hemophagocytic syndrome
and characterised by recurrent IM-like symptom (Kimura et al,
2001). The clonal expansion of EB infected NK- or T-cells is seen in
patients with both nasal NK/T-cell lymphoma and CAEBV
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sinfection, suggesting that the two diseases might partly share a
similar mechanism by which EBV affect host cellular genes. The
question has thus arisen why a subset of patients with CAEBV
infection develop nasal NK/T-cell lymphoma.
This study aimed to investigate the virus–host interaction in
two types of EBV-associated NK/T-cell LPD, which may clarify the
possible association between infection and cancer. We attempted
transcriptional profiling of EBV genes using a novel viral DNA
microarray, HHV-4 Viruchip
s, in addition to host cellular gene
expression profiling using human oligonucleotide DNA micro-
arrays, seeking to evaluate the possible role of EBV–host
interaction in nasal NK/T-cell lymphoma and CAEBV infection.
MATERIALS AND METHODS
Cells
We used six cell lines with EBV-associated T/NK-cell LPD: SNK-1*,
SNK-6* and SNT-8* were isolated from nasal NK/T-cell lympho-
ma, and SNK-10, SNT-13 and SNT-16 were isolated from the
peripheral blood of patients with CAEBV infection (Zhang et al,
2003). Asterisks were added to the designation of cell lines to easily
distinguish those that were established from NK/T-cell lymphoma
to those from patients with CAEBV infection. SNK-1*, SNK-6*,
SNK-10 showed an NK cell phenotype, while SNT-8*, SNT-13,
SNT-16 had a T-cell phenotype (Zhang et al, 2003). All the SNK/T
cells had monoclonal EBV genomes identical to the original EBV-
infected cells of the respective patients, and detailed characteristics
of the cell lines were reported previously (Zhang et al, 2003). SNK/
T cells were maintained in RPMI1640 with 10% heat-inactivated
human serum and 700Uml
 1 of IL-2. The cell line, B95-8 was used
as a positive control of lytic infection of EBV (Miller et al, 1972). A
peripheral blood mononuclear cells obtained from a patient with
acute phase of IM (IM-a cells), a Burkitt lymphoma cell line
(Akata) and a EBV-transformed lymphoblastoid cell line (LCL-a)
were also used (Shimizu et al, 1994). The original patient
specimens from which IM-a and LCL-a established were acquired
after obtaining written informed consent from the patients.
A human lymphoid cell lines, Peer and WaY were used EBV
negative controls (Ravid et al, 1980; Zhang et al, 2003).
Quantification of EBV DNA copy number in SNK/T cells
DNA was extracted from both cells and the supernatants using a
QIAamp Blood Kit (Qiagen, Basel, Switzerland). To determine
whether encapsidated EBV rather than fragments of EBV DNA
were present in culture supernatant of the SNK and SNT cell lines,
800ml of supernatant of cell lines was treated with or without
DNase I (Invitrogen, Carlsbad, CA, USA) by which cell-free EBV
DNA molecules are digested (Gallagher et al, 1999). Real-time
quantitative polymerase chain reaction (PCR) was done using an
ABI PRISM 7700 Sequence Detection System as reported
previously (Aritaki et al, 2001).
RNA isolation and cDNA labelling
Total RNA was extracted using a RNeasy Mini Kit (Qiagen,
Germantown, MD, USA). For microarray analysis of host genes,
mRNA was purified using an Oligotext-dT30oSuper4mRNA
Purification Kit (Takara, Shiga, Japan). Total RNA (40mg) or 1mg
of mRNA were reverse transcribed into cDNA and labelled by
cyanine 5 (Cy5)-conjugated deoxyuracil triphosphate (dUTP)
or cyanine 3 (Cy3)-conjugated dUTP (Amersham Biosciences,
Piscataway, NJ, USA) using a LabelStar Array kit (Qiagen),
according to the supplier’s instruction. For the EBV DNA
microarray, EBV-specific primer and control housekeeping gene
specific primers (Celonex Inc., Edmonton, Alberta, Canada) were
used instead of oligo-dT primer in the current study.
EBV DNA microarray
The EBV DNA chip, HHV-4 Viruchip
s (Celonex Inc.), was made
up of triplicate spots of 70-mer oligonucleotide specific probes for
each EBV transcription unit. The detailed information of the EBV
DNA chip was deposited in an NCBI gene expression omnibus
(GEO, accession number: GPL1917). Four human genes were
included in order to standardise the amount of applied cDNA and
to normalise the signals between samples and references. In all, 17
genes of HIV were also printed to exclude nonspecific hybridisa-
tion. For a dual colour analysis of EBV gene expression, the cDNA
obtained from EBV-negative cells was labelled with Cy3 as a
reference, and cDNA obtained from EBV-positive cells was labelled
with Cy5. The EBV gene expression was then compared among
various types of EBV infected cells. Hybridisation was performed
following the same procedure as we recently reported in detail
using the HHV-6B Viruchip
s (Ohyashiki et al, 2005a). Briefly,
HHV-4 Viruchip
s was prehybridised in buffer containing
5  SSC, 0.1% sodium dodecyl sulphate (SDS) and 1% BSA, then
hybridised with labelled probes in ArrayHyb low-temperature
hybridisation buffer (Sigma-Aldrich co., St Louis, MO, USA)
containing 1/100 vol. of salmon testis DNA (Sigma-Aldrich Co.) at
421C for 16h. The HHV-4 Viruchip
s was washed with microarray
washing buffer (Sigma-Aldrich Co.) according to the manu-
facture’s instruction.
DNA microarray analysis of host cellular genes
To analyse host cellular gene expression patterns, we have
designed two types of pathway focused low-density oligonucleotide
microarrays (Novusgene Inc., Tokyo, Japan) which contains 528
selected genes related to cell growth, cell cycle, apoptosis,
transcription, DNA repair and cell stress responses (GEO accession
number: GPL1919 and GPL 1920). This DNA chip was made up of
tetra-plicate spots of 60-mer highly specific oligonucleotide
probes. For DNA microarray analysis of host genes, we used 1mg
of mRNA obtained from cell lines. For dual colour analysis, normal
human lymphocyte mRNA was purchased from Ambion (Austin,
TX, USA), and utilised as a reference, and then cellular gene
expression were compared among SNK/T cells. mRNA (1mg) was
labelled with Cy-3 or Cy-5 and hybridisation was carried out
automatically using GeneTAC Hybstation (Genomic Solutions,
AnnArbor, MI, USA) according to the supplier’s instruction. The
conditions of hybridisation were 551C for 2h, 501C for 2h and
461C for 2h, then 421C for 12h.
Data analysis and statistic validation
The hybridised signals were scanned by GenePix 4000B Microarray
Scanner (Axon Instruments, Union City, CA, USA) as raw data.
The scanned data were normalised, verified and analysed using the
Genomic Profiler software
s (Mitsui Knowledge Industry Inc.,
Tokyo, Japan) as reported previously (Ohyashiki et al, 2005a;
Takaku et al, 2005). First, the value was adjusted by subtraction of
background fluorescence of an equivalent area. Analysis was
carried out by taking the median signal of the probe value for each
transcript set, and the 75% rank for the total hybridisation was
calculated. Microarray data obtained from three independent
experiments were then verified in a single file. The normalised log
data of fluorescence ratio (Cy5 to Cy3), which was quantified for
each gene to reflect the relative abundance of gene in each
experimental sample compared with reference sample, were
deposited in GEO. To validate the amount of applied cDNA in
EBV DNA microarray, we performed normalisation by five human
housekeeping genes as reported previously, since we used
uninfected cells as references (Ohyashiki et al, 2005a). This
normalisation procedure is different from those used in human
DNA microarray (global normalisation) (Takaku et al, 2005). For
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GeneSifter
s (VizXLabs, Seattle, WA, USA). Analysis of variance
(ANOVA), and Student’s t-test, were performed using GeneSifter
s.
Values of Po0.05 were considered to be indicate a statistically
significant difference and theBenjamini-Hochberg algorithm was
used for estimation of false discovery rates.
Real-time Reverse transcriptase PCR (RT-PCR)
To confirm the results of microarray, we performed RT-PCR by
ABI PRISM 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) as reported elsewhere (Ohyashiki et al,
2005b). For relative quantification of EBV gene expression, the
level of gene expression was expressed as the percent of those in
SNK-6* cells.
For absolute quantification of BARF1, BHRF1 and BZLF1 gene
expressions, we constructed plasmids that contain each amplified
fragment using a pT7Blue T vector-2 kit (Novagen, Darmstadt,
Germany) to generate a standard curve, then the amount of EBV
gene expression in each sample was expressed as copy numbers
per microgram of RNA with respect to the standard curve. Primers
and probe sets for the EBV gene are described in Table 1.
For quantification of human gene expression, we utilised
Taqman gene expression assays (Applied Biosystems), and the
amount of gene expression in each sample was evaluated as a
percent with respect to the standard curve generated from a
serial dilution of quantitative PCR human reference total RNA
(Stratagene, La Jolla, CA, USA).
PCR direct sequencing of BARF1 gene
PCR-direct sequencing of BARF-1 was carried out using BigDye
Terminator ver3.1 (Perkin-Elmer Cetus, Fremont, CA, USA). We
designed four pairs of primers for nucleotide sequence analysis of
BARF1. BARF1-1F: 50-CCTCACA AACACAGAATCTG and BARF1-
1R: 50-GAGACCGAGGTCACCAAG; BARF1-2F:50-CCGCTTTCTT
GGGTGAGC and BARF1-2R: 50-GCAAA TGGCGGTGTTATGAA;
BARF1-3F: 50-GTCACCGCTGCC AACATCTC and BARF1-3R:
50TTGCGGGTGGATAGCCTC; BARF1-4F: 50GTCTC AGTTC CCAG
ACTTCT and BARF1-4R: 50AAATAGTTCCAGGTGACAGC.
Expression of Zta in SNK/T cells
Western blot analysis for expression of Zta was performed
according to the procedure previously reported (Zhang et al,
2003). Briefly, cells were washed twice in phosphate-buffered saline
(PBS) and cell pellets were lysed in electrophoresis buffer and
boiled for 10min. The equivalent of 2.5 10
5 cells was loaded onto
each lane of an 8% Tris-glycine gel. The separated protein was
blotted onto a filter and blocked in 5% skimmed milk, then
incubated with Anti-Zta (Anti-Z Replication Activator) (Argene,
Varilhes, FRANCE) in 5% skimmed milk in PBS for 90min at room
temperature. After washing, the blots were incubated for 30min
with horseradish peroxidase (HRP)-linked anti-mouse IgG.
(Amersham Biosciences, Buckinghamshire, UK). Signals were
visualised using a ECL Western blotting detection reagents and
analysis system (Amersham Biosciences).
RESULTS
EBV virion was not detected in the supernatant
of SNK/T cells
EBV load of the SNK/T cells were ranged from 3.4 10
5 to
3.5 10
6copiesmg
 1 of DNA (Figure 1). EBV DNA was also
detected in the untreated supernatant of SNK/T cells; however,
EBV DNA was undetectable in any supernatant after DNase
digestion. This indicates that the EBV DNA present in the
untreated supernatant of SNK/T cells consisted of naked DNA
fragments rather than virions, which must be encapsidated. In
contrast, the EBV copy numbers of B95-8 cells showing lytic
infection was high in both cells and DNase-treated supernatant.
Unlike in B95-8 cells, it is likely that active viral replication does
not take place in SNK/T cells, although we could not completely
rule out the possibility that only a small portion of SNK/T cells
entered the lytic cycle which could not be detected by the current
PCR assay. We did not detect any EBV in either cells or
supernatant of Peer.
EBV gene expression profiling using a EBV microarray,
HHV-4 Viruchip
s
To compare the general gene expression pattern, we first
investigated the transcriptional profiling of EBV using cells with
various types of EBV infection. The tentative cluster analysis of
EBV gene expression (K-mean, by Genomic Profiler
s) showed
marked heterogeneity among cell lines (Figure 2, See the GEO
accession number, GSE2414 to retrieve all the data of EBV gene
expression). The EBV gene expression pattern of cells from a
patient in the acute phase of IM exhibited a distinct feature, which
did not mimic any other samples used in the current study. As
peripheral blood cells in IM patients may be composed of EBV
lytically infected cells as well as latently infected cells (Bauer et al,
2005), we found that a subset of EBV lytic genes including BZLF1
in Group 5 were expressed in IM-a cells. In Akata cells, a limited
Table 1 Sequences of primers and probes for real-time RT-PCR
Target Oligo Sequence: Genebank accession #NC_001345 Coordinates
BARF1 Forward primer GGTGAAGCCTCTAACGCTGTCT 165866–165887
Reverse primer TCACGGTGCATGTCACAGTAAG 165927–165948
Probe TCCACTCCGAAAGGTCTCAGTTCCCAG 165889–165915
BHRF1 Forward primer CAGGACATTGTGTTGTAACCAGTCT 54711–54735
Reverse primer GCCTTCGCTGGCTTCTAACAT 54772–54792
Probe CTCCTTACTATGTTGTGGACCTGTCAGTTCGTG 54737–54769
BDLF3 Forward primer TAGTCGTGGTCAAGGTCGTAGACT 130874–130897
Reverse primer ACAACGGCTGTGACTACACCAT 130928–130949
Probe TGCTAGGACCCGATGCCGACG 130904–130924
BFLF2 Forward primer GCACATGAACCTGGGACCTATT 56467–56488
Reverse primer CTTCGGCCACAGCCTGACT 56519–56534
Probe ATGCAGATCTCGCAGTGAGACCCCA 56490–56514
BZLF1 Forward primer GGAGGAATGCGATTCTGAACTAG 102449–102466
Reverse primer GCTTAAACTTGGCCCGGC 102506–102528
Probe TTTTCTGGAAGCCACCCGATTCTTGTA 102468–102494
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EBNR1 (Group 1) was detected. Subsets of lytic gene such as BARF1
and BKRF3 (Group 3) were also expressed, which is consistent with
the previous reports that a small portion of EBV positive Akata cells
expressed lytic antigens (Sheng et al, 2003). In LCL-a, considerable
numbers of both lytic and latent genes were expressed. Of note is that
the expression profile of the above mentioned three cell lines showed
its own distinct pattern of EBV gene expression.
In SNK/T cells, we found a wide variation of transcriptional
profiles. The expression patterns of SNK-6*, SNT-8* and SNT-13
somewhat mimic to those in LCL-a (genes in Group 3), while those
cell line had monoclonal EBV genomes identical to the original
EBV-infected cells of the respective patients. In contrast, the
expression pattern of SNK-10 did not take after those of any other
cell lines. The gene expression patterns in SNK/T cells, which were
highly variable, shared some common characteristics. In general,
the latent genes, such as BKRF1, LMP1, LMP2 (AþB), EBER1,
EBER2 and BARF0 were detected in SNK/T cells. We could not find
any difference of EBV gene expression between cells established
from NK/T-cell lymphoma and those from CAEBV infection by
EBV DNA microarray, however, it is notable that some lytic genes,
such as BARF1, BKRF3, BDLF3, BFLF2 and BHRF1, were detected
in most of the SNK/T cells.
Quantitative relationship between EBV gene expression
by microarray and a real-time RT-PCR
In the current study, we found some discrepancy between data
obtained from the EBV microarray and our previous observations
using RT-PCR and Western blotting. For instance, the expression
of LMP-1 gene in SNK-10 was negative by EBV DNA microarray
despite the fact that our previous study showed LMP1 expression
by Western blotting (Zhang et al, 2003). Since we used EBV
uninfected cell as the reference, value 0 (normalised log 2 ratio)
means the background subtracted fluorescence intensities after
careful normalisation of the amount of applied cDNA may be equal
in the sample and the references. It was possibly due to nonspecific
hybridisation. We, therefore, arbitrarily determined the cutoff level
as 1.5, however, unlike with human DNA microarray, it was rather
difficult to determine the appropriate cut-off value in EBV DNA
microarray. To validate the results obtained from the HHV-4
Viruchip
s, we therefore compared the normalised log 2 ratio of
the median calculated by microarray analysis and the relative
expression level of EBV by a real-time RT-PCR. The normalised
log ratio of the median was associated with the results obtained
from real-time RT-PCR, although we found some discrepancy
between data obtained from the two methods especially when the
normalised log ratio was relatively low (Figure 3A). In contrast, we
found significant correlation between the EBV gene expression
levels by microarray analysis and those by real-time RT-PCR, when
normalised log ratios were extremely high (i.e., LCL-a) or
undetectable (i.e., IM-a).
BARF1, BHRF1 and BZLF1 expression in SNK/T cells
infection
Our previous study mainly focused on the latent gene expression
in SNK/T cells (Zhang et al, 2003), however, the transcriptional
profiling of EBV led us to consider several lytic genes which may
play some role in the development of EBV infected SNK/T cells.
The quantitative real-time RT-PCR revealed that BHRF1 was
expressed in SNK/T cells, but the expression was the lower at a
2log scale compared to B95-8 and LCL-a. In contrast, the level of
BARF1 gene expression in SNK/T cells was equivalent to that in
LCL. We, therefore, sought to determine the sequence variants
within the BARF1 sequences by PCR-direct sequencing. We found
several sequence variations with respects to the sequence of B95-8
(NC_001345) within the BARF1 (i.e., G to A at the position of
165554 and T to C at 165589 in SNK-1 and SNK-8; T to C at 165545
in SNT-16). Although the expression level of BZLF1, which
encodes the immediate-early gene products Zta detected by DNA
microarray was relatively low in SNK/T cells, real-time RT-PCR
showed that the expression of BZLF1 was detected in all the SNK/T
cells (Figure 3B). It is noteworthy that the copy numbers of BZLF1
in SNK/T cells derived from CAEBV infection was significantly
higher than those from NK/T-cell lymphomas (P¼0.049). Western
blot analysis for the expression of Zta showed that all the SNK/T
cells were positive for Zta, confirming the results obtained from
real-time RT-PCR (Figure 3C).
The common molecular signature of host cellular genes
in SNK/T cells
In SNK/T cell lines, selection of clones with growth advantage in
vitro might occur during the immortalisation process, despite
being established in a clinically different disease. We first
investigated the common molecular signature of SNK/T cells (to
retrieve all the data of normalised log ratio, see GEO accession
number: GSE2414). Differential expression was analysed using a
GeneSifter
s (Figure 4A). Genes with elevated expression levels in
SNK/T cells (expression level in the sample was four-fold greater
than in control lymphocytes) were listed in Table 2A. We found
that a subset of genes, which may play regulatory roles in
apoptosis, including IL1A, BCL6, TNFRSF10D, RIPK2 and PDCD1,
was upregulated in SNK/T cells. It is notable that upregulation of
CDK2, which is related to cell cycle regulation, HSPCA, encoding
heat shock protein 90 and ELF4, which may be linked to NK/T cell
proliferation, were common biological characteristics of SNK/T
cells. Genes related to cell adhesion, such as CDH1, CD44, CUL5
and CDH9 were also upregulated in SNK/T cells. In contrast, a
subset of genes, such as IL12A, which is known to be an interferon-
g inducer, was remarkably downregulated (expression level in the
sample was four-fold lower than in control lymphocytes) in SNK/T
cells (Table 2B).
The difference of host gene expression between cell
lines established from NK/T lymphoma and those
from CAEBV infection
To ascertain whether the host cellular gene expression of SNK/T
cells established from nasal NK/T-cell lymphoma patients is
0
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Figure 1 Quantification of EBV viral genome in SNK/T cells. The
outlined bar indicates copy numbers of EBV in SNK/T cells. The hatched
bar indicates the copy numbers of EBV in untreated supernatant. The black
bar indicates the copy numbers of encapsidated EBV in DNase-treated
supernatant that was only seen in B95-8 cells. In SNK/T cells, viral load is
observed in both cells and untreated supernatant, whereas EBV DNA was
undetectable after DNase treatment. Primers and probes are as follows:
the forward primer; 50-GGAACCTGGTCAT CCTTGC, the reverse
primer; 50-ACGTGCATGGACCGGTTAAT, and probe 50-FAM- CG
CAGGCACTCGTA CTGCTCGCT-TAMRA.
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sdifferent from that of cells established from CAEBV infection
patients, we next compared the gene expression pattern between
two groups, one with cells from NK/T-cell lymphoma and the other
from CAEBV infection. Eventually, we found several genes with
expression levels significantly higher in cell lines established
from NK/T-cell lymphoma than those from CAEBV infection
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Figure 2 Transcriptional profiling of EBV in SNK/T cells and EBV associated diseases. The cluster analysis (K-mean) was done using Genomic Profiler
s
software. This colour map shows that genes whose expression is greater than EBV negative control is shown as red (see legend). The molecular signature of
SNK/T cells is highly variable, but shares partly common features (see the text). Notable genes are indicated by arrowheads, and asterisks indicate lytic genes.
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s(Table 3): FGF14, PDCD4, PCNA, MAP2K4, ITGAX and AKAP2
were preferentially expressed in SNK/T cells established from nasal
NK/T lymphoma. The expression levels of genes, FGF14, PCNA
and PDCD4 were compatible with the results obtained from real-
time RT-PCR (Figure 4B).
DISCUSSION
This may be the first report dealing with the molecular signature of
EBV in nasal NK/T-cell lymphoma and CAEBV infection. More-
over, our DNA microarray approach from aspects of viral and host
gene expression might provide insight into the complex genetic
process underlying the interaction between EBV and NK/T-cells.
Evidence suggests that the oncogenic potential of EBV lies largely
in a set of cell cycle promoting EBV genes that are expressed
during latency, therefore, latency associated genes, such as LMP1,
are likely to play a major role in the viral life cycle by causing
amplification and distribution of infected cells (Huen et al, 1995;
Zimber-Strobl et al, 1996). In contrast, recent studies demon-
strated that herpesviruses, such as the human cytomegalovirus,
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Figure 3 (A) Quantitative relationship between EBV gene expression by microarray and a real-time RT-PCR. Circles: SNK/T cells, Triangle: IM-a cells, and
Solid dot: Akata. In general, the normalised log ratio of median was basically associated with the results obtained from real-time RT-PCR. When normalised
log ratios were extremely high (i.e., LCL-a) or undetectable (i.e., IM-a), there was a significant correlation between the EBV gene expression levelsb y
microarray analysis and those by a real-time RT-PCR. (B) Quantification of EBV gene expression by real-time RT-PCR. BARF1 is consistently expressed in all
the SNK/T cells. The expression of BHRF1 is also seen in all the SNK/T cells, but the expression levels are approximately 2log lower than those in LCL. (C)
Western blot analysis of Zta in SNK/T cells. WaY was used as the negative control, and B95-8 was used as the positive control. All the SNK/T cells were
weakly positive for Zta.
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swhich belongs to the b-herpesviruses, can actively block cell cycle
progression during lytic infection, indicating that viral replication
suppresses cell growth and vice versa (Wei et al, 1994; Jault et al,
1995; Lu and Shenk, 1996). The same argument can be applied to
EBV infection.
A group of abundantly expressed RNAs that are encoded by the
BamHI region of the EBV genome were originally identified in
NPC (Young and Rickinson, 2004). Although there were more than
20 BamHI fragments in EBV, we specially marked down BARF1,
which is generated from the BamHI fragment region, originally
identified as an early antigen expressed on induction of the EBV
lytic cycle. BARF1 shares limited homology to intracellular
adhesion molecule 1 (ICAM-1) and human colony stimulating
factor 1 receptor (hCSF-1 receptor) and display oncogenic activity
in both EBV negative Akata cells and human Louckes
B-lymphocytes (Sheng et al, 2003)). Recent studies demonstrated
that BARF1 is a secreted protein that is expressed as a latent
protein in EBV-associated NPC and gastric carcinoma (Decaussin
et al, 2000; zur Hausen et al, 2000). In the present study, we found
that BARF1 was expressed in all the SNK/T cells. While the
pathological significance of the sequence variations within BARF1
remains uncertain, we postulate that BARF1 expression might be
linked to the pathogenesis in NK/T-LPD, in keeping with its role in
NPC (Decaussin et al, 2000).
In the current study, we also found expression of several EBV
lytic genes (i.e., BHRF1 which shows partial sequence homology to
the human bcl-2 proto-oncogene, BKRF3, BDLF3 and BFLF2) in all
of the SNK/T cells. Despite the fact that SNK/T cells express lytic
genes, we could not find any detectable amount of virion DNA in
the supernatant of SNK/T cells, suggesting that the vast majority of
SNK/T cells have abortive EBV infection. Of note is that the BZLF1
was detected in all the SNK/T cells by quantitative RT-PCR and we
confirmed expression of Zta by a Western blotting analysis. A
recent study by Kimura et al (2005) demonstrated that patients
with T-cell type CAEBV infection had higher titers of immuno-
globulin G against early EBV antigen, suggesting lytic cycle
infection. Taken together with our results, EBV lytic gene may play
an important role in the pathogenesis of NK/T-cell LPD.
Probably because of the technical pitfalls of viral microarray
analysis (Ohyashiki et al, 2005a), some discrepancy was seen in the
genes detected by microarray analysis compared with the results
obtained from RT-PCR studies. Since the sensitivity of the DNA
microarray seemed to be different from that of conventional
assays, we conclude that EBV microarray technology is suitable for
determining global gene expression patterns in EBV-related
diseases but inappropriate for genes especially when EBV gene
expression was low. The discrepancy should be resolved by
increasing the resolution of microarrays, by extensive and
technical repeats of hybridisation, by using proper reference, by
performing an appropriate normalisation procedure and by
carefully characterising the nature of viral transcriptome. The
primary goal of this study, the transcriptional profiling of EBV,
might provide new insight into the EBV gene expression of T/NK-
cell LPD, which traditionally has been categorised as latency type II
infection. While the use of EBV microarrays is still in its infancy,
this emerging technology will improve our understanding of host-
pathogen interaction.
The secondary goal of this study was to investigate the common
molecular properties of SNK/T cells. Mainly due to the hetero-
geneity of biological properties among SNK/T cells, we found great
variations among cell lines regardless of the cell lineage. We
intended to focus the genes in SNK/T cells whose expression level
in the sample was four times greater than in control lymphocytes.
Theoretically, the comparison of cells of the same lineage at a
similar differentiation stage would be ideal for human gene
expression analysis, however, in practical terms this was difficult
to perform, since samples of both T and NK lineage were included
in this study. Even though all the SNT series are of T-cell lineage,
SNT-8, and -13 have gdT-cell phenotype and SNT-16 has gd T-cell
phenotype. We, therefore, used normal lymphocytes as the same
reference RNA for dual colour microarray analysis, and then
compared the host gene expression levels in both T- and NK-cell
lines. It is notable that the expression level of TNFRSF10D, which
inhibits toll-like receptor (TRAIL) mediated apoptosis, was
significantly higher in SNK/T cells. A recent study demonstrated
that a lytic EBV gene, BHRF-1 drastically inhibits TRAIL-mediated
apoptosis in BJAB cells (Kawanishi et al, 2002). Matrix-based
comparative genomic hybridisation (matrix-CGH) analysis
demonstrated that TNFRSF10D is one of the pathologically
relevant genes in mantle cell lymphoma (Kohlhammer et al,
2004). In addition, upregulation of RIPK2, which accelerates the
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Figure 4 (A) The common molecular signature of SNK/T cells. ANOVA
analysis was performed by GeneSifter
s using microarray analysis data
deposited in GEO (GSE2414). Genes whose expression levels are 4-fold
greater (left) or lower (right) in SNK/T cells compared to those in normal
lymphocytes were navigated by GeneSifter
s. A list of gene names is also
shown in Table 2. (B) Genes preferentially expressed in lymphoma cell
lines. Quantitative real-time RT PCR of FGF14, PDCD4, and PCNA in
SNK/T cells. The expression levels are higher in cell lines established from
NK/T lymphoma consistent with the results obtained from microarray
analysis.
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effect in SNK/T cells. Therefore, we reasoned that antiapoptotic
pathways might be involved to the virus–host interaction in SNK/
T cells whether or not cells were derived from NK/T-cell
lymphoma.
Another important issue that we should address is that the
expression of CDK2, which is considered to be a key cell-cycle
regulatory factor, was upregulated in SNK/T cells. Interestingly, the
expression of BZLF1, which encodes Zta was high in a subset of
SNK/T cells. Zta may carry out its function through a complex
series of interactions with multiple cell cycle control proteins, such
as p53 and pRb (Rodriguez et al, 2001; Lin et al, 2004) Obviously, it
must be clarified whether the Zta-mediated cell cycle control
mechanism in SNK/T cells is similar to that reported in other types
of EBV-related B-cell malignancies. We also found overexpression
of HSPCA, which encodes heat shock protein 90, which has
recently been reported as a pathologically relevant gene candidate
in mantle-cell lymphoma by proteomic analysis (Ghobrial et al,
2005). Marked downregulation of IL12A in SNK/T cells allowed
us to consider the possibility to adoptive immunotherapy with
EBV-specific cytotoxic-T-lymphocytes (Robertson et al, 2005).
The clonal expansion of EBV-infected T or NK cells is a common
feature seen in both NK/T-cell lymphoma and CAEBV infection.
Although SNK/T cells share common biological properties,
Table 2 Common molecular signature in SNK/T cells derived from both nasal NK/T lymphoma and CAEBV
GeneBank
accession # Gene name Molecular function
(A) Upregulated genes whose expression level was greater than four-fold compared to those in normal lymphocytes
NM_000575 IL1A Interleukin 1, alpha Negative regulation of apoptosis, innate immune response
NM_004360 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) Cell adhesion
NM_005348 HSPCA Heat shock 90kDa protein 1, alpha Cell stress
NM_001706 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) Regulation of cell proliferation
NM_005018 PDCD1 Programmed cell death 1 Response to pest/pathogen/parasite
NM_005235 ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 Signal transduction
NM_001798 CDK2 Cyclin-dependent kinase 2 Cell cycle, regulated by CDK inhibitors, such as p21Cip
1(CDKN1A), p27Cip 1(CDKN1B)
NM_004536 BIRC1 Baculoviral IAP repeat-containing 1 Negative regulation of apoptosis
XM_030326 CD44 CD44 antigen Extracellular matrix
NM_001964 EGR1 Early growth response 1 Transcription
NM_003478 CUL5 Cullin5 Extracellular matrix
NM_016279 CDH9 Cadherin 9, type 2 (T1-cadherin) Cell adhesion
NM_001421 ELF4 E74-like factor 4 (ets domain transcription factor) Transcription, DNA-dependent, NK T-cell proliferation
NM_003821 RIPK2 Receptor-interacting serine-threonine kinase 2 Apoptosis, activation of MAPK pathway and NF kappa B pathway
NM_005408 CCL13 Chemokine (C-C motif) ligand 13 Innate immune response
NM_006534 NCOA3 Nuclear receptor coactivator 3 Transcription, DNA-dependent
NM_001606 ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2 Metabolism
NM_003840 TNFRSF10D Tumor necrosis factor receptor superfamily, member 10d Negative regulation of apoptosis
NM_006164 NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 Transcription, DNA-dependent
NM_005252 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog Innate immune response, cell growth
(B) Downregulated genes whose expression level was lower than 4.0 fold compared to those in normal lymphocytes.
NM_000877 IL1R1 Interleukin 1 receptor, type I Response to pest/pathogen/parasite
NM_000882 IL12A Interleukin 12A (natural killer cell stimulatory factor 1) (IL12A), T-cell independent induction of interferon (IFN)-gamma
NM_002697 POLR2G POU domain, class 2, transcription factor 1 DNA repair
NM_030754 SAA2 Serum amyloid A2 Extracellular matrix
NM_002002 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23A) Immunoglobulin binding
NM_002945 RPA1 Replication protein A1, 70kDa Response to DNA damage stimulus
NM_002914 RFC2 Replication factor C (activator 1) 2, 40kDa DNA replication
NM_001982 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 Metabolism
NM_005427 TP73 Tumor protein p73 Induction of apoptosis by intracellular signals
ANOVA analysis was performed by GeneSifter using microarray analysis data deposited in GEO (GSE2414). Statistically significant (Po0.05) genes were listed above.
Table 3 Genes preferentially expressed in cell lines derived from nasal NK/T lymphoma (SNK-1*, SNK-6*, SNT-8*) compared to those with CAEBV
(SNK-10, SNT-13, SNT-16)
GeneBank accession # Gene name Molecular function P-value
NM_004115 FGF14 Growth factor activity 6.75E-06
NM_014456 PDCD4 Cell death 0.001200532
NM_002592 PCNA Cell growth 0.001395258
NM_007203 AKAP2 Signal transduction 0.001985058
NM_000887 ITGAX Cell adhesion, integrin-mediated signaling pathway 0.02959104
NM_003010 MAP2K4 Protein modification 0.030605858
NM_003250 THRA Regulation of transcription 0.030747275
NM_001089 ABCA3 Cellular process 0.042526959
NM_002446 MAP3K10 Positive regulation of apoptosis, activation of JNK activity 0.042943068
Pairwise analysis (t-test) was performed by GeneSifter using microarray analysis data deposited in GEO (GSE2414): Group 1: Cell lines derived from CAEBV, Group 2: Cell lines
derived from NK/T-cell lymphoma. Correction was done by Benjamin Hochberg method.
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s revealed that a subset of
genes including PDCD4 may contribute to the development of
lymphoma. We could not completely exclude the possibility that
this was possibly due to in vitro selection of EB virus infected NK
or T cells, therefore, further studies using samples obtained from
patients will be required to rigorously address this issue.
Although the number of cell lines at hand was limited in the
current study, our results convincingly suggest the possibility that
certain EBV genes, such as BZLF1 could be a therapeutic target for
EBV-related NK/T-cell LPD. Moreover, our data provide a basis for
further studies on the identification of pathogenically and
clinically relevant host cellular genes, such as TNFRSF10D,
CDK2, Hsp90, IL12A and PDCD4. Since the biology of EBV
infection in vivo still remains unclear, to investigate the molecular
signature of both virus and host might introduce a novel target for
antineoplastic therapies including vaccines.
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